MBRX on Nasdaq

Moleculin Biotech, Inc.

American pharmaceutical preparations company based in Houston. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerMBRX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersHouston, United States2
  • Incorporated inDE3
  • Business address5300 Memorial Drive, Suite 950, Houston, Tx 770073
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300IB1TLJZCHEO3532
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57932652

See how the biggest companies compare on our leaderboards

We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, and we expect to have an interim unblinding of data in mid-2026 and an additional unblinding in the second half of 2026, thereby concluding Part A of the two-part trial. We believe such early visibility for a pivotal registration-enabling trial is unique in that stakeholders will receive preliminary safety and efficacy data long before the concl…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-223.6%Return on equity5
-$22.7MFree cash flow5

Financial statements

Revenue6789105$0 in 2025
02019: $0$020192020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$020242025: $0$02025
Operating income6789105-$25.1M in 2025+43% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$17.5M-$17.5M20192020: -$19.7M-$19.7M2020+13%2021: -$23.0M-$23.0M2021+16%2022: -$30.6M-$30.6M2022+33%2023: -$29.6M-$29.6M2023−3%2024: -$26.6M-$26.6M2024−10%2025: -$25.1M-$25.1M2025−6%
Net income6789105-$33.6M in 2025+154% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$13.2M-$13.2M20192020: -$17.4M-$17.4M2020+31%2021: -$15.9M-$15.9M2021−8%2022: -$29.0M-$29.0M2022+83%2023: -$29.8M-$29.8M2023+3%2024: -$26.0M-$26.0M2024−12%2025: -$33.6M-$33.6M2025+29%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$0$0
Research and development$15.9M$17.7M
General and administrative$9.1M$8.8M
Depreciation and amortization$90.0K$126.0K
Total operating expenses$25.1M$26.6M
Loss from operations-$25.1M-$26.6M
Gain from change in fair value of warrant liabilities$24.4M$0
Loss on issuance of warrant liabilities-$31.0M$0
Transaction costs allocated to warrant liabilities-$1.4M$0
Loss on extinguishment of warrant liabilities-$614.0K$0
Other (expense) income, net-$20.0K$43.0K
Interest income, net$105.0K$550.0K
Net loss-$33.6M-$26.0M
Warrant deemed dividend-$104.0K$0
Net loss available to common stockholders-$33.7M-$26.0M
Net loss per common share - basic and diluted (in dollars per share)-$28.42-$189.14
Weighted average common shares outstanding, basic and diluted (in shares)1.2M shares137.7K shares
Foreign currency translation$51.0K-$32.0K
Comprehensive loss-$33.5M-$26.1M

Compare Moleculin Biotech, Inc. with another company

Leadership

Who has led Moleculin Biotech, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Walter Klemp V.2016–now

Chair

  1. Walter Klemp V.2016

President

  1. Donald H. Picker2016
  2. Walter Klemp V.2018–now

Chief financial officer

  1. Louis Ploth Jr.2016
  2. Jonathan P. Foster2016–now

Chief operating officer

  1. Donald H. Picker2016
20202025
Board members and other officers (8)

Timeline

  1. Jun 7, 2016New chief executive Walter Klemp V. becomes CEO13
  2. Jul 28, 2015Founded Moleculin Biotech, Inc. is founded2

Filings

451 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 235 major events, 77 insider forms, 9 large holders, 106 other. The latest 20:

  1. Oct 15, 2026S-8 EDGAR
  2. Oct 9, 20268-K EDGAR
  3. Oct 5, 20268-K EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Sep 28, 20268-K EDGAR
  6. Sep 25, 20268-K EDGAR
  7. Sep 23, 20268-K EDGAR
  8. Sep 18, 20268-K EDGAR
  9. Sep 14, 20268-K EDGAR
  10. Aug 31, 20268-K EDGAR
  11. Aug 25, 2026SCHEDULE 13D EDGAR
  12. Aug 25, 2026SCHEDULE 13D EDGAR
  13. Aug 24, 2026DEFA14A EDGAR
  14. Aug 24, 2026DEF 14A EDGAR
  15. Aug 21, 2026424B5 EDGAR
  16. Aug 14, 2026PRE 14A EDGAR
  17. Aug 14, 20268-K EDGAR
  18. Aug 13, 202610-Q EDGAR
  19. Aug 10, 2026SCHEDULE 13G EDGAR
  20. Aug 6, 2026SCHEDULE 13G EDGAR

The 451 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 12 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 3, 2026Foster Jonathan P.Chief Financial OfficerBuy293,333Form 4
Aug 3, 2026KLEMP WALTER VCEO and PresidentBuy533,333Form 4
Aug 3, 2026PICKER DONALD HChief Science OfficerBuy173,333Form 4
Jun 23, 2025Foster Jonathan P.Chief Financial OfficerBuy270,270$0.37$100.0KForm 4
Jun 23, 2025KLEMP WALTER VCEO and PresidentBuy675,675$0.37$250.0KForm 4
Dec 26, 2023Foster Jonathan P.Chief Financial OfficerBuy28,986$0.69$20.0KForm 4
Dec 26, 2023George Robert E.DirectorBuy14,493$0.69$10.0KForm 4
Dec 26, 2023KLEMP WALTER VCEO and PresidentBuy188,404$0.69$130.0KForm 4
Nov 25, 2022KLEMP WALTER VCEO and PresidentBuy45,000$1.28$57.6KForm 4
Nov 21, 2022KLEMP WALTER VCEO and PresidentBuy22,500$1.15$25.9KForm 4
Nov 17, 2022KLEMP WALTER VCEO and PresidentBuy24,742$1.02$25.2KForm 4
Nov 16, 2022KLEMP WALTER VCEO and PresidentBuy85,213$0.97$82.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Geode Capital Management, LLC47,252$131.8K0.0%+14,923
Vanguard Capital Management LLC42,215$117.8K0.0%+28,346
Vanguard Fiduciary Trust Co29,883$83.4K0.0%+23,811
XTX Topco Ltd22,942$64.0K0.0%New
Morgan Stanley20,036$55.9K0.0%+20,000
Rockefeller Capital Management L.P.15,000$41.9K0.0%+10,579
Tower Research Capital LLC (TRC)3,514$9.8K0.0%+1,679
Citigroup Inc2,674$7.5K0.0%New
Barclays PLC621$1.7K0.0%New
BlackRock, Inc.491$1.4K0.0%No change
EFG International AG434$1.2K0.0%No change
Jones Financial Companies Lllp360$1.2K0.0%New
Wells Fargo & Company/mn200$5580.0%New
NFSG Corp114$3180.0%No change
SBI Securities Co., Ltd.44$1230.0%+1
Danske Bank A/s2$60.0%No change
CVA Family Office, LLC1$30.0%No change
Osaic Holdings, Inc.1$20.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30